Treatment of graft-versus-host disease
First Claim
Patent Images
1. A method of treating symptoms of graft-versus-host disease in a subject identified as suffering from graft-versus-host disease, comprising:
- (A) obtaining a homogeneous population of single cell-derived clonal multipotent bone marrow cells based on cell density from a biological sample of bone marrow, comprising;
(i) allowing the biological sample to settle by gravity in a first container producing a first supernatant of lower density cells;
(ii) transferring the first supernatant directly without undergoing centrifugation to a second container of growth medium and allowing cells to settle to the bottom producing a second supernatant of lower density cells;
(iii) transferring the second supernatant directly without undergoing centrifugation to a third container of growth medium and allowing cells to settle to the bottom, producing a third supernatant of lower density cells;
(iv) transferring the third supernatant directly without undergoing centrifugation to another container of growth medium and allowing cells to settle to the bottom, producing another supernatant of lower density cells;
(v) allowing single-cell derived colonies to appear on the bottom of the container of step (iv);
(vi) isolating the single-cell derived colonies; and
(vii) expanding cells from the single-cell derived colonies in a further other container of growth medium to obtain the homogeneous population of single cell-derived clonal multipotent bone marrow cells, and(B) administering to the subject in need thereof a therapeutically effective amount of the homogeneous population of single cell-derived clonal multipotent bone marrow cells obtained in (A) to inhibit T-cell activity from a donor marrow.
3 Assignments
0 Petitions
Accused Products
Abstract
This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient.
12 Citations
18 Claims
-
1. A method of treating symptoms of graft-versus-host disease in a subject identified as suffering from graft-versus-host disease, comprising:
-
(A) obtaining a homogeneous population of single cell-derived clonal multipotent bone marrow cells based on cell density from a biological sample of bone marrow, comprising; (i) allowing the biological sample to settle by gravity in a first container producing a first supernatant of lower density cells; (ii) transferring the first supernatant directly without undergoing centrifugation to a second container of growth medium and allowing cells to settle to the bottom producing a second supernatant of lower density cells; (iii) transferring the second supernatant directly without undergoing centrifugation to a third container of growth medium and allowing cells to settle to the bottom, producing a third supernatant of lower density cells; (iv) transferring the third supernatant directly without undergoing centrifugation to another container of growth medium and allowing cells to settle to the bottom, producing another supernatant of lower density cells; (v) allowing single-cell derived colonies to appear on the bottom of the container of step (iv); (vi) isolating the single-cell derived colonies; and (vii) expanding cells from the single-cell derived colonies in a further other container of growth medium to obtain the homogeneous population of single cell-derived clonal multipotent bone marrow cells, and (B) administering to the subject in need thereof a therapeutically effective amount of the homogeneous population of single cell-derived clonal multipotent bone marrow cells obtained in (A) to inhibit T-cell activity from a donor marrow. - View Dependent Claims (2, 3)
-
-
4. A method of treating symptoms of graft-versus-host disease in a subject identified as suffering from graft-versus-host disease, comprising:
-
(A) obtaining a homogeneous population of single cell-derived clonal multipotent bone marrow cells based on cell density from a biological sample of bone marrow, comprising; (i) allowing the biological sample to settle by gravity in a first container producing a first supernatant of lower density cells; (ii) transferring the first supernatant directly without undergoing centrifugation to a second container of growth medium and allowing cells to settle to the bottom producing a second supernatant of lower density cells; (iii) transferring the second supernatant directly without undergoing centrifugation to a third container of growth medium and allowing cells to settle to the bottom, producing a third supernatant of lower density cells; (iv) transferring the third supernatant directly without undergoing centrifugation to a fourth container of growth medium and allowing cells to settle to the bottom, producing a fourth supernatant of lower density cells; (v) transferring the fourth supernatant directly without undergoing centrifugation to another container of growth medium and allowing cells to settle to the bottom, producing another supernatant of lower density cells; (vi) allowing single-cell derived colonies to appear on the bottom of the container of step (v); (vii) isolating the single-cell derived colonies; and (viii) expanding cells from the single-cell derived colonies in a further other container of growth medium to obtain the homogeneous population of single cell-derived clonal multipotent bone marrow cells, and (B) administering to the subject in need thereof a therapeutically effective amount of the homogeneous population of single cell-derived clonal multipotent bone marrow cells obtained in (A) to inhibit T-cell activity from a donor marrow. - View Dependent Claims (5, 6)
-
-
7. A method of treating symptoms of graft-versus-host disease in a subject identified as suffering from graft-versus-host disease, comprising:
-
(A) obtaining a homogeneous population of single cell-derived clonal multipotent bone marrow cells based on cell density from a biological sample of bone marrow, comprising; (i) allowing the biological sample to settle by gravity in a first container producing a first supernatant of lower density cells; (ii) transferring the first supernatant directly without undergoing centrifugation to a second container of growth medium and allowing cells to settle to the bottom producing a second supernatant of lower density cells; (iii) transferring the second supernatant directly without undergoing centrifugation to a third container of growth medium and allowing cells to settle to the bottom, producing a third supernatant of lower density cells; (iv) transferring the third supernatant directly without undergoing centrifugation to a fourth container of growth medium and allowing cells to settle to the bottom, producing a fourth supernatant of lower density cells; (v) transferring the fourth supernatant directly without undergoing centrifugation to a fifth container of growth medium and allowing cells to settle to the bottom, producing a fifth supernatant of lower density cells; (vi) transferring the fifth supernatant directly without undergoing centrifugation to another container of growth medium and allowing cells to settle to the bottom, producing another supernatant of lower density cells; (vii) allowing single-cell derived colonies to appear on the bottom of the container of step (vi); (viii) isolating the single-cell derived colonies; and (ix) expanding cells from the single-cell derived colonies in a further other container of growth medium to obtain the homogeneous population of single cell-derived clonal multipotent bone marrow cells, and (B) administering to the subject in need thereof a therapeutically effective amount of the homogeneous population of single cell-derived clonal multipotent bone marrow cells obtained in (A) to inhibit T-cell activity from a donor marrow. - View Dependent Claims (8, 9)
-
-
10. A method of treating graft-versus-host disease in a subject identified as suffering from graft-versus-host disease, comprising:
-
(A) obtaining a homogeneous population of single cell-derived clonal multipotent bone marrow cells based on cell density from a biological sample of bone marrow, comprising; (i) allowing the biological sample to settle by gravity in a first container producing a first supernatant of lower density cells; (ii) transferring the first supernatant directly without undergoing centrifugation to a second container of growth medium and allowing cells to settle to the bottom producing a second supernatant of lower density cells; (iii) transferring the second supernatant directly without undergoing centrifugation to a third container of growth medium and allowing cells to settle to the bottom, producing a third supernatant of lower density cells; (iv) transferring the third supernatant directly without undergoing centrifugation to another container of growth medium and allowing cells to settle to the bottom, producing another supernatant of lower density cells; (v) allowing single-cell derived colonies to appear on the bottom of the container of step (iv); (vi) isolating the single-cell derived colonies; and (vii) expanding cells from the single-cell derived colonies in a further other container of growth medium to obtain the homogeneous population of single cell-derived clonal multipotent bone marrow cells, and (B) administering to the subject in need thereof a therapeutically effective amount of the homogeneous population of single cell-derived clonal multipotent bone marrow cells obtained in (A) to inhibit T-cell activity from a donor marrow. - View Dependent Claims (11, 12)
-
-
13. A method of treating graft-versus-host disease in a subject identified as suffering from graft-versus-host disease, comprising:
-
(A) obtaining a homogeneous population of single cell-derived clonal multipotent bone marrow cells based on cell density from a biological sample of bone marrow, comprising; (i) allowing the biological sample to settle by gravity in a first container producing a first supernatant of lower density cells; (ii) transferring the first supernatant directly without undergoing centrifugation to a second container of growth medium and allowing cells to settle to the bottom producing a second supernatant of lower density cells; (iii) transferring the second supernatant directly without undergoing centrifugation to a third container of growth medium and allowing cells to settle to the bottom, producing a third supernatant of lower density cells; (iv) transferring the third supernatant directly without undergoing centrifugation to a fourth container of growth medium and allowing cells to settle to the bottom, producing a fourth supernatant of lower density cells; (v) transferring the fourth supernatant directly without undergoing centrifugation to another container of growth medium and allowing cells to settle to the bottom, producing another supernatant of lower density cells; (vi) allowing single-cell derived colonies to appear on the bottom of the container of step (v); (vii) isolating the single-cell derived colonies; and (viii) expanding cells from the single-cell derived colonies in a further other container of growth medium to obtain the homogeneous population of single cell-derived clonal multipotent bone marrow cells, and (B) administering to the subject in need thereof a therapeutically effective amount of the homogeneous population of single cell-derived clonal multipotent bone marrow cells obtained in (A) to inhibit T-cell activity from a donor marrow. - View Dependent Claims (14, 15)
-
-
16. A method of treating graft-versus-host disease in a subject identified as suffering from graft-versus-host disease, comprising:
-
(A) obtaining a homogeneous population of single cell-derived clonal multipotent bone marrow cells based on cell density from a biological sample of bone marrow, comprising; (i) allowing the biological sample to settle by gravity in a first container producing a first supernatant of lower density cells; (ii) transferring the first supernatant directly without undergoing centrifugation to a second container of growth medium and allowing cells to settle to the bottom producing a second supernatant of lower density cells; (iii) transferring the second supernatant directly without undergoing centrifugation to a third container of growth medium and allowing cells to settle to the bottom, producing a third supernatant of lower density cells; (iv) transferring the third supernatant directly without undergoing centrifugation to a fourth container of growth medium and allowing cells to settle to the bottom, producing a fourth supernatant of lower density cells; (v) transferring the fourth supernatant directly without undergoing centrifugation to a fifth container of growth medium and allowing cells to settle to the bottom, producing a fifth supernatant of lower density cells; (vi) transferring the fifth supernatant directly without undergoing centrifugation to another container of growth medium and allowing cells to settle to the bottom, producing another supernatant of lower density cells; (vii) allowing single-cell derived colonies to appear on the bottom of the container of step (vi); (viii) isolating the single-cell derived colonies; and (ix) expanding cells from the single-cell derived colonies in a further other container of growth medium to obtain the homogeneous population of single cell-derived clonal multipotent bone marrow cells, and (B) administering to the subject in need thereof a therapeutically effective amount of the homogeneous population of single cell-derived clonal multipotent bone marrow cells obtained in (A) to inhibit T-cell activity from a donor marrow. - View Dependent Claims (17, 18)
-
Specification